Medeor Therapeutics

About

Medeor Therapeutics is a biotechnology company that dedicates to dedicates to the development of personalized cellular immunotherapies.

South San Francisco,California,United States
1 - 10

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $57M
Industries: Biotechnology,Pharmaceutical,Therapeutics
Founded date: Jan 1, 2012
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: Medeor Therapeutics, Inc.

Medeor Therapeutics is a developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

$75.80M

Medeor Therapeutics has raised a total of $75.80M in funding over 2 rounds. Their latest funding was raised on Jan 22, 2018 from a Grant round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 22, 2018	Grant	$18.80M	1	California Institute for Regenerative Medicine	—	Detail
Nov 27, 2017	Series B	$57M	5	RA Capital Management	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

6

Medeor Therapeutics is funded by 6 investors. California Institute for Regenerative Medicine and RA Capital Management are the most recent investors.

Investor Name	Lead Investor	Funding Round
California Institute for Regenerative Medicine	Yes	Grant
RA Capital Management	Yes	Series B
6 Dimensions Capital	—	Series B
Sofinnova Investments	—	Series B
Vivo Capital	—	Series B
WuXi Healthcare Ventures	—	Series B